For the quarter ending 2026-03-31, ALBT had $666,904 increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| (income) loss from equity method investment | - | 0 | 0 | 392,677 |
| Income Loss From Equity Method Investments | - | 392,677 | - | - |
| Income from equity method investment - lab services mso | - | 0 | - | - |
| AIGenerated Polishing | - | 94,553 | - | - |
| Corporate Other | - | 7,889,483 | - | - |
| Other operating expenses | - | 7,984,036 | - | - |
| Interest Expense Nonoperating | - | 1,456,694 | - | - |
| Interest expense | - | 1,456,694 | - | - |
| Gains Losses On Extinguishment Of Debt | - | -9,076,587 | - | - |
| Loss on extinguishment of debt | - | -9,076,587 | - | - |
| Other income (expense) | - | 605,767 | - | - |
| Loss on extinguishment of debt | - | 0 | 0 | 9,076,587 |
| Net loss from continuing operations | -4,376,680 | -17,518,873 | - | - |
| Credit loss provision | - | - | - | 1,650,000 |
| Depreciation and amortization of intangible assets | 563,158 | -38,652 | 44,335 | 88,760 |
| Net loss | - | - | -254,268 | -15,940,709 |
| Change in straight-line rent receivable | - | - | 12,621 | -58,586 |
| Amortization of operating lease right-of-use asset | 16,398 | 15,633 | 15,127 | 33,628 |
| Rent receivable | - | - | -1,747 | 6,381 |
| Stock-based compensation and service expense | 319,819 | 393,484 | 661,280 | 761,698 |
| Security deposit | - | 79 | 80 | 17,332 |
| Amortization of debt issuance costs and debt discount | 189,417 | -18,898 | 31,339 | 1,123,971 |
| Distribution of earnings from equity method investment | - | 0 | 0 | - |
| Deferred leasing costs | - | - | 23,732 | - |
| Change in fair market value of derivative liability | 1,276,889 | -66,267 | -25,130 | -446,816 |
| Deferred leasing costs | - | - | - | 15,877 |
| Impairment of laboratory equipment | - | 0 | - | - |
| Prepaid expense and other assets | 37,854 | -162,331 | -70,288 | 254,918 |
| Distribution of earnings from equity method investment | - | - | - | 0 |
| Debt modification charge | - | 0 | - | - |
| Accrued liabilities and other payables | -796,128 | 764,819 | -235,640 | 1,220,868 |
| Accrued liabilities and other payables - related parties | - | 0 | 0 | 0 |
| Operating lease obligation | -15,398 | -15,633 | -15,127 | -33,628 |
| Net cash used in operating activities | - | - | -1,360,735 | -3,027,822 |
| Net cash used in operating activities from continuing operations | -2,860,379 | -4,580,620 | - | - |
| Improvement of commercial real estate | - | - | 35,865 | - |
| Cash acquired on acquisition | - | 14,026 | - | - |
| Proceeds from sale of equity method investment | 280,500 | 280,500 | 693,500 | 95,000 |
| Payment for equity interest purchase | - | 0 | 0 | 0 |
| Net cash provided by investing activities from continuing operations | -472,135 | - | 657,635 | 95,000 |
| Net cash provided by (used in) investing activities from continuing operations | - | 1,083,026 | - | - |
| Proceeds from issuance of convertible debt | - | 0 | 200,000 | - |
| Advance from pending sale of noncontrolling interest in subsidiary | - | 0 | -100,000 | 149,972 |
| Proceeds from issuance of convertible preferred stock | - | 0 | 300,000 | 0 |
| Payments of convertible preferred stock issuance costs | - | 0 | 10,000 | - |
| Proceeds from issuance of bridge loan | - | 300,000 | - | - |
| Proceeds from issuance of common stock and warrants | - | 0 | 475,500 | - |
| Payments of offering costs | - | 12,051 | 30,265 | 22,336 |
| Proceeds from stock subscription liability | - | 0 | 150,000 | - |
| Proceeds from issuance of convertible debt and warrants | - | 0 | - | - |
| Payments of convertible debt issuance costs | - | 0 | 0 | 0 |
| Repayments of bridge loan | 250,000 | 0 | - | - |
| Repayments of convertible debt | 200,000 | 0 | 0 | 0 |
| Proceeds from issuance of debt | 1,164,000 | - | 0 | - |
| Payments of debt issuance costs | 34,000 | - | - | - |
| Proceeds from equity offering | - | 0 | 0 | - |
| Proceeds received from the february 2026 private offering | 3,249,412 | - | - | - |
| Proceeds from stock subscription liability | - | - | - | 150,000 |
| Disbursements for equity offering costs | - | 0 | 0 | - |
| Disbursements for the february 2026 private offering costs | 492,600 | - | - | - |
| Net cash provided by financing activities from continuing operations | 3,436,812 | 287,949 | 835,235 | 277,636 |
| Net cash used in operating activities from discontinued operations | -231,956 | -407,434 | - | - |
| Net cash used in investing activities from discontinued operations | - | -35,865 | - | - |
| Net cash flows used in discontinued operations | -231,956 | -443,299 | - | - |
| Effect of exchange rate on cash - continuing operations | 41,927 | -9,691 | 264 | 409 |
| Net increase (decrease) in cash | 666,904 | -26,713 | 132,399 | -2,654,777 |
| Cash - beginning of period | 109,091 | 333,931 | 2,856,309 | - |
| Cash - end of period | 775,995 | 109,091 | 333,931 | - |
Avalon GloboCare Corp. (ALBT)
Avalon GloboCare Corp. (ALBT)